For people living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.1

How LUMAKRAS
may help

SEE HOW

Once-daily
dosing

LEARN MORE

Find financial
support

EXPLORE OPTIONS

The first once-daily oral treatment1

For people living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.1

Not Chemotherapy2

LUMAKRAS™ is a trademark of Amgen Inc.

References: 1. LUMAKRAS™ (sotorasib) Patient Information. Thousand Oaks, CA: Amgen; 2021. 2. LUMAKRAS™ (sotorasib) Prescribing Information. Thousand Oaks, CA: Amgen 2021.